Login to Your Account

Special ASCO 2013 Edition

Clovis Lung Data Wow; PARP Inhibitor Makes Impression, too

By Randy Osborne
Staff Writer

Monday, June 3, 2013

Analysts, inspecting early stage data, hailed the "paradigm-changing" potential in the treatment of at least one set of non-small-cell lung cancer (NSCLC) patients with Clovis Oncology Inc.'s oral CO-1686, for which results from Phase I/II trials were reported at ASCO 2013.

Helped also by early data with an ovarian-cancer therapy, Boulder, Colo.-based Clovis' shares (NASDAQ:CLVS) blew through the roof, ending Monday at $74.59, up $38.01 , 104 percent, after trading as high as $86.29.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription